Formulary Focus: PCSK9 Drug Prices May Lead Payers To Impose Coverage Restrictions
Anticipating annual pricing of up to $10,000 per patient for PCSK9 cholesterol-lowering drugs that will be prescribed for life, payers are taking a very close look at how to limit use to the patients who most need to take the drugs in the new class instead of low-cost statins.
You may also be interested in...
Analysis published in the Journal of the American Medical Association is the latest to argue that PCSK9 inhibitors are not cost-effective.
Report released as soon-to-be committee chair Ron Wyden, D-OR, assembles plans for drug pricing legislation in the new Democratic-controlled Senate.
Former CMS acting administrator Andy Slavitt says agency’s direction during Biden administration depends on nominee, but trust fund’s looming insolvency will be ‘an issue you can’t avoid.’ The president’s priorities around health equity, racial justice and mental health will make their way into CMS policy and demonstration models, Slavitt suggests.